Evidence map›Paper›PMID 40876952›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of

Adrien Holzgreve, Astrid Delker, Zachary Ells, Julia Brosch-Lenz, Lena M Unterrainer, John Nikitas, Shaojun Zhu, Maria M Contreras, Hamzah Alam, Rejah M Nabong and 9 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Beyond [BMC cancer · 2026
    Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Adrien HolzgreveAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Astrid DelkerDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Zachary EllsAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Julia Brosch-LenzInstitute of Nuclear Medicine Inc., Bethesda, Maryland.
Lena M UnterrainerAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
John NikitasAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Shaojun ZhuAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Maria M ContrerasAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Hamzah AlamAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Rejah M NabongAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Stephanie LiraAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Arseniy VasilyevDepartment of Medicine Statistics Core, Department of Medicine's Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, UCLA, Los Angeles, California.
Lillian ChenDepartment of Medicine Statistics Core, Department of Medicine's Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, UCLA, Los Angeles, California.
Tristan GroganDepartment of Medicine Statistics Core, Department of Medicine's Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, UCLA, Los Angeles, California.
David ElashoffDepartment of Medicine Statistics Core, Department of Medicine's Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, UCLA, Los Angeles, California.
Catherine A MeyerAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Magnus DahlbomAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Jérémie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; jcalais@mednet.ucla.edu.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

[

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantClinical Trials, Phase II as TopicHumansMaleNeoplasm MetastasisProstate-Specific AntigenRadioisotopesRadiopharmaceuticalsRandomized Controlled Trials as TopicDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177PluvictoProstate-Specific AntigenPSMA-617RadioisotopesRadiopharmaceuticals[177Lu]Lu-PSMA-617mCRPCmetastatic castration-resistant prostate cancerprostate-specific membrane antigenPSMAradiopharmaceutical therapyRPTSPECT/CTtherapy response assessmenttreatment holidays

Identifiers

PMID40876952
PMCPMC12487728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.